SEOUL — August 27 — DIA, a global organization of life sciences professionals, will facilitate in-depth discussions on recent advancements in regulatory science, pharmacovigilance, the impact of real-world data (RWD), and the application of artificial intelligence (AI) in drug development during the DIA Asia Meeting, to be held Sept. 25 at The-K Hotel in Seoul.

The meeting will unite industry representatives, government officials, regulators, academics, and patients from across East Asia and allow them to interact, network, and debate the most pressing issues facing the life sciences.

"Cooperation among regulatory bodies has never been more necessary — not just across the region, but globally," said Young Joo Park, DIA's Vice President and Managing Director for Korea, Singapore, and Southeast Asia. "By bringing the biopharmaceutical industry and regulators closer together, we can foster a stronger collaborative environment that promotes transparency and shared knowledge while addressing the challenges that come with taking new approaches to drug and device development."

Younjoo Park, Director General of the National Institute of Food and Drug Safety Evaluation (NIFDS) at South Korea's Ministry of Food and Drug Safety (MFDS), will deliver the meeting's keynote address on the nation's recent advancements in regulatory science.

Senior regulators, including Heesung Kim, Director of the Biologics Division at the MFDS; John Lim, Executive Director of the Centre of Regulatory Excellence (CoRE) at Duke-National University of Singapore Medical School; and Yoshiaki Uyama, Associate Executive Director of Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Meghana Chalasani, Associate Director for Clinical Trial Innovation at the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research, will address the recent changes in regulatory science and their effect on healthcare. Additional representatives from the FDA and the European Medicines Agency (EMA) will also attend.

In addition, experts will present examples of RWD's role in indication expansion, new drug approvals, and post-marketing studies, and pharmaceutical industry leaders will explore the latest developments and practical applications of AI, including its use in indication selection, patient enrichment, AI-supported diagnosis, operational excellence, and AI-powered medical writing. The integration of AI technologies in safety surveillance, signal detection, and risk management, with a focus on enhancing patient safety outcomes through collaboration, will also be topics of conversation.

"This year's program reflects the rapid pace of innovation in our field," said Marwan Fathallah, DIA's President and Chief Executive Officer. "We are looking forward to once again bringing together the brightest minds to lead the charge in healthcare innovation and sparking discussions that will redefine drug development and regulatory science for the benefit of patients everywhere."

DIA, which is celebrating its 60th year, has also partnered with the Korea Regulatory Science Center (KRSC) to organize a workshop titled "Future Development Direction and Regulatory Science for Innovative Drugs" on Sept. 26, following the conclusion of the Asia Annual Meeting, at The-K Hotel in Seoul. The workshop will allow attendees to discuss regulatory perspectives and techniques that accelerate the development of innovative medicines through regulatory collaborations.

Early-bird registration for each event has been extended until Sept. 13, and a 25% discount is available for those who attend both. Media members can request credentials by emailing diaglobal@gregoryfca.com.

About DIA

DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.

Media Contact

Denise DiMeglio
Gregory FCA
denise@gregoryfca.com
+1.610.228.2102